Umbilical cord blood for cardiovascular cell therapy: From promise to fact

Santiago Roura; Josep Maria Pujal; Antoni Bayes-Genis

doi:10.1111/j.1749-6632.2012.06515.x

Umbilical cord blood for cardiovascular cell therapy: From promise to fact

Santiago Roura, Josep Maria Pujal, Antoni Bayes-Genis

Department of Medicine

Research output: Contribution to journal › Article › Research › peer-review

20 Citations (Scopus)

Abstract

Endothelial recovery and cell replacement are therapeutic challenges for cardiovascular medicine. Initially employed in the treatment of blood malignancies due to its high concentration of hematological precursors, umbilical cord blood (UCB) is now a non-controversial and accepted source of both hematopoietic and non-hematopoietic progenitors for a variety of emerging cell therapies in clinical trials. Here, we review the current therapeutic potential of UCB, focusing in recent evidence demonstrating the ability of UCB-derived mesenchymal stem cells to differentiate into the endothelial lineage and to develop new vasculature in vivo. © 2012 New York Academy of Sciences.

Original language	English
Pages (from-to)	66-70
Journal	Annals of the New York Academy of Sciences
Volume	1254
Issue number	1
DOIs	https://doi.org/10.1111/j.1749-6632.2012.06515.x
Publication status	Published - 1 Jan 2012

Keywords

Cardiovascular diseases
Mesenchymal stem cell
Umbilical cord blood

Access to Document

10.1111/j.1749-6632.2012.06515.x

Fingerprint Dive into the research topics of 'Umbilical cord blood for cardiovascular cell therapy: From promise to fact'. Together they form a unique fingerprint.

Cite this

@article{914f06c2fa8946fd96f79c36a63c3265,

title = "Umbilical cord blood for cardiovascular cell therapy: From promise to fact",

abstract = "Endothelial recovery and cell replacement are therapeutic challenges for cardiovascular medicine. Initially employed in the treatment of blood malignancies due to its high concentration of hematological precursors, umbilical cord blood (UCB) is now a non-controversial and accepted source of both hematopoietic and non-hematopoietic progenitors for a variety of emerging cell therapies in clinical trials. Here, we review the current therapeutic potential of UCB, focusing in recent evidence demonstrating the ability of UCB-derived mesenchymal stem cells to differentiate into the endothelial lineage and to develop new vasculature in vivo. {\textcopyright} 2012 New York Academy of Sciences.",

keywords = "Cardiovascular diseases, Mesenchymal stem cell, Umbilical cord blood",

author = "Santiago Roura and Pujal, {Josep Maria} and Antoni Bayes-Genis",

year = "2012",

month = jan,

day = "1",

doi = "10.1111/j.1749-6632.2012.06515.x",

language = "English",

volume = "1254",

pages = "66--70",

journal = "Annals of the New York Academy of Sciences",

issn = "0077-8923",

number = "1",

}

TY - JOUR

T1 - Umbilical cord blood for cardiovascular cell therapy: From promise to fact

AU - Roura, Santiago

AU - Pujal, Josep Maria

AU - Bayes-Genis, Antoni

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Endothelial recovery and cell replacement are therapeutic challenges for cardiovascular medicine. Initially employed in the treatment of blood malignancies due to its high concentration of hematological precursors, umbilical cord blood (UCB) is now a non-controversial and accepted source of both hematopoietic and non-hematopoietic progenitors for a variety of emerging cell therapies in clinical trials. Here, we review the current therapeutic potential of UCB, focusing in recent evidence demonstrating the ability of UCB-derived mesenchymal stem cells to differentiate into the endothelial lineage and to develop new vasculature in vivo. © 2012 New York Academy of Sciences.

AB - Endothelial recovery and cell replacement are therapeutic challenges for cardiovascular medicine. Initially employed in the treatment of blood malignancies due to its high concentration of hematological precursors, umbilical cord blood (UCB) is now a non-controversial and accepted source of both hematopoietic and non-hematopoietic progenitors for a variety of emerging cell therapies in clinical trials. Here, we review the current therapeutic potential of UCB, focusing in recent evidence demonstrating the ability of UCB-derived mesenchymal stem cells to differentiate into the endothelial lineage and to develop new vasculature in vivo. © 2012 New York Academy of Sciences.

KW - Cardiovascular diseases

KW - Mesenchymal stem cell

KW - Umbilical cord blood

U2 - 10.1111/j.1749-6632.2012.06515.x

DO - 10.1111/j.1749-6632.2012.06515.x

M3 - Article

VL - 1254

SP - 66

EP - 70

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

IS - 1

ER -